Market Size of North America Kidney Cancer Therapeutics & Diagnostics Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2019 - 2022 |
| CAGR | 5.80 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
North America Kidney Cancer Therapeutics & Diagnostics Market Analysis
The North America Kidney Cancer Therapeutics & Diagnostics Market is expected to register a CAGR of 5.8% during the forecast period. The major factors driving the growth of the market in the North America region is due to the rising number of kidney cancer cases and increased R&D expenditure of the pharmaceutical companies.
According to GLOBOCAN 2018, in 2018, there were about 60,336 new kidney cancer cases and the mortality was approximately 15,333 cases in the United States.
Furthermore, changes in lifestyle, excessive smoking, increased consumption of alcohol, and a rise in obesity because of sedentary life routines lead to the growing incidence of the disease. Thus, owing to the above factors the North America kidney cancer therapeutics & diagnostics market is expected to significant growth over the forecast period.
North America Kidney Cancer Therapeutics & Diagnostics Industry Segmentation
As per the scope of the report, kidney cancer is a type of cancer that starts in kidney cells. The kidney cancer therapeutics and diagnostics involve therapy and diagnostics methods that are used for the treatment of renal cancer. The North America kidney cancer therapeutics & diagnostics market is segmented by cancer type, component and geography.
North America Kidney Cancer Therapeutics & Diagnostics Market Size Summary
The North America Kidney Cancer Therapeutics & Diagnostics Market is poised for significant expansion, driven by an increasing incidence of kidney cancer and heightened research and development investments by pharmaceutical companies. Lifestyle changes, such as increased smoking, alcohol consumption, and obesity due to sedentary habits, have contributed to the rising prevalence of kidney cancer in the region. Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer among adults, accounting for a substantial portion of renal cell carcinoma cases. The detection of ccRCC often involves imaging tests or biopsies, where a small sample from the tumor is examined microscopically. The availability of targeted therapies, including cabozantinib, axitinib, sunitinib, sorafenib, and pazopanib, further supports the market's growth trajectory.
The competitive landscape of the North America Kidney Cancer Therapeutics & Diagnostics Market is moderately consolidated, with key players such as Bayer AG, F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc, Abbott Laboratories, Amgen Inc, and Seattle Genetics leading the charge. These companies are actively engaged in product innovation and research and development activities to advance technologies and treatment options. This dynamic environment is fostering market growth, as these firms strive to enhance their offerings and capture a larger market share. The combination of high disease prevalence, robust diagnostic procedures, and effective treatment therapies underscores the market's promising outlook over the forecast period.
North America Kidney Cancer Therapeutics & Diagnostics Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Rising Number of Kidney Cancer Cases
-
1.2.2 Increased R&D Expenditure of Pharmaceutical Companies
-
-
1.3 Market Restraints
-
1.3.1 High Cost Associated with Treatment
-
1.3.2 Preference for Generic Drugs
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 By Cancer Type
-
2.1.1 Clear cell RCC
-
2.1.2 Papillary RCC
-
2.1.3 Chromophobe RCC
-
2.1.4 Urothelial carcinoma/Transitional cell carcinoma
-
2.1.5 Other Kidney cancers (Wilms tumor, Renal sarcoma, Collecting duct RCC)
-
-
2.2 By Component
-
2.2.1 Drugs
-
2.2.1.1 Therapeutic Class
-
2.2.1.1.1 Targeted Therapy
-
2.2.1.1.2 Immunotherapy
-
2.2.1.1.3 Other Therapeutic Class
-
-
2.2.1.2 Pharmacologic Class
-
2.2.1.2.1 Angiogenesis Inhibitors
-
2.2.1.2.2 Monoclonal Antibodies
-
2.2.1.2.3 mTOR Inhibitors
-
2.2.1.2.4 Cytokine Immunotherapy (IL-2)
-
-
-
2.2.2 Diagnostics
-
2.2.2.1 Biopsy
-
2.2.2.2 Imaging Tests
-
2.2.2.3 Blood Tests
-
2.2.2.4 Other Diagnostics
-
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
-
North America Kidney Cancer Therapeutics & Diagnostics Market Size FAQs
What is the current North America Kidney Cancer Therapeutics & Diagnostics Market size?
The North America Kidney Cancer Therapeutics & Diagnostics Market is projected to register a CAGR of 5.80% during the forecast period (2024-2029)
Who are the key players in North America Kidney Cancer Therapeutics & Diagnostics Market?
Pfizer Inc, F. Hoffmann-La Roche Ltd, Bayer AG, Novartis AG and Amgen Inc are the major companies operating in the North America Kidney Cancer Therapeutics & Diagnostics Market.
